RedHill Biopharma's Oral COVID-19 Candidate Shows Preclinical Action Against Delta Variant

RedHill Biopharma Ltd RDHL has announced preliminary results of a new preclinical study for its COVID-19 treatment candidate, opaganib.
Related: RedHill's Novel Late-Stage Pills Hold Promise Against COVID-19 and its Variants
Data showed potent inhibition by opaganib of Delta variant replication while maintaining cell viability at relevant concentrations.
Today's data adds to the previously reported work that showed opaganib also inhibits Alpha, Beta, and Gamma SARS-CoV-2 variants.
Opaganib's global 475-patient Phase, 2/3 study in hospitalized patients with COVID-19, has completed its treatment and follow-up phase, and study top-line results are upcoming.
Furthermore, the Phase 2/3 study has passed four Data Safety Monitoring Board reviews, including a futility review, and extends the entire opaganib safety database to more than 460 patients.
Earlier this week, RedHill Biopharma announced two US patents covering opaganib for Ebola virus disease, with patent protection until 2035, and RHB-104 for bacterial infections, with protection through 2029.
Price Action: RDHL shares are up 8.64% at $7.80 during the premarket session on the last check Thursday.